Gilde invests in Pharmaline - Gilde Healthcare

Gilde invests in Pharmaline

December 20, 2012

Gilde has invested in Pharmaline, based in Oldenzaal the Netherlands. Pharmaline is specialized in large scale pharmaceutical compounding. The company is one of the few Dutch players whose facilities and production processes are structured to comply with the guidelines of the Dutch Health Care Inspectorate (IGZ) and Good Manufacturing Practice (GMP).

The external pharmaceutical compounding market is a relatively new niche market in the Netherlands and accounts for approximately 5% of all prescribed drugs in public pharmacies. This market came into existence around 2008. At that time, regulatory pressure forced pharmacies to increase efficiency and to further professionalize the pharmacy value chain. Since 2009, Pharmaline has been at the forefront to develop this new market segment and the company is taking the lead in its professionalization by offering pharmacies a unique and high quality outsourcing opportunity of the full range of outsourced pharmacy preparations. The company is growing rapidly and currently serves about 20% of all public pharmacies in the Netherlands.

The investment team of Gilde Healthcare Services is well versed in this market and sees ample growth opportunities for the company. The Gilde team actively supports the management of the company in expanding the organization and strengthening its market position.

Jan Verwaal, managing director of Pharmaline, comments enthusiastically:

“I am very pleased that Gilde joins us as a new shareholder and I am confident that with the valuable knowledge, experience and capital of Gilde, Pharmaline will flourish in the years to come.”

Jasper van Gorp, partner at Gilde adds:

“Currently, the market for pharmaceutical compounding is professionalizing rapidly, Pharmaline perfectly anticipates to this trend, which provides huge opportunities. We are excited about our partnership with Pharmaline and are confident about the continued success of the company.”

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024